CTLA4 and head and neck squamous cell carcinoma: This synergistic effect between EVO and ICIs has also been observed in other tumor types, such as head and neck squamous cell carcinoma (HNSCC), where the combination of EVO and anti-CTLA-4 therapy significantly improved survival compared to immunotherapy alone [194].